Androgen-regulated SPARCL1 in the tumor microenvironment inhibits metastatic progression

Paula Hurley, Robert M. Hughes, Brian W. Simons, Jessie Huang, Rebecca M. Miller, Brian Shinder, Michael C. Haffner, David Esopi, Yasunori Kimura, Javaneh Jabbari, Ashley E. Ross, Nicholas Erho, Ismael A. Vergara, Sheila F. Faraj, Elai Davicioni, George J. Netto, S Yegnasubramanian, Steven An, Edward M. Schaeffer

Research output: Contribution to journalArticle

Abstract

Prostate cancer is a leading cause of cancer death in men due to the subset of cancers that progress to metastasis. Prostate cancers are thought to be hardwired to androgen receptor (AR) signaling, but AR-regulated changes in the prostate that facilitate metastasis remain poorly understood. We previously noted a marked reduction in secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) expression during invasive phases of androgen-induced prostate growth, suggesting that this may be a novel invasive program governed by AR. Herein, we show that SPARCL1 loss occurs concurrently with AR amplification or overexpression in patient-based data. Mechanistically we demonstrate that SPARCL1 expression is directly suppressed by androgen-induced AR activation and binding at the SPARCL1 locus via an epigenetic mechanism, and these events can be pharmacologically attenuated with either AR antagonists or HDAC inhibitors. We establish using the Hi-Myc model of prostate cancer that in Hi-Myc/Sparcl1-/-mice, SPARCL1 functions to suppress cancer formation. Moreover, metastatic progression of Myc-CaP orthotopic allografts is restricted by SPARCL1 in the tumor microenvironment. Specifically, we show that SPARCL1 both tethers to collagen in the extracellular matrix (ECM) and binds to the cell's cytoskeleton. SPARCL1 directly inhibits the assembly of focal adhesions, thereby constraining the transmission of cell traction forces. Our findings establish a new insight into AR-regulated prostate epithelial movement and provide a novel framework whereby SPARCL1 in the ECM microenvironment restricts tumor progression by regulating the initiation of the network of physical forces that may be required for metastatic invasion of prostate cancer.

Original languageEnglish (US)
Pages (from-to)4322-4334
Number of pages13
JournalCancer Research
Volume75
Issue number20
DOIs
StatePublished - Oct 15 2015

Fingerprint

Tumor Microenvironment
Androgens
Cysteine
Androgen Receptors
Prostatic Neoplasms
Proteins
Prostate
Extracellular Matrix
Androgen Receptor Antagonists
Neoplasm Metastasis
Neoplasms
Histone Deacetylase Inhibitors
Focal Adhesions
Traction
Cytoskeleton
Epigenomics
Allografts
Cause of Death
Collagen
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hurley, P., Hughes, R. M., Simons, B. W., Huang, J., Miller, R. M., Shinder, B., ... Schaeffer, E. M. (2015). Androgen-regulated SPARCL1 in the tumor microenvironment inhibits metastatic progression. Cancer Research, 75(20), 4322-4334. https://doi.org/10.1158/0008-5472.CAN-15-0024

Androgen-regulated SPARCL1 in the tumor microenvironment inhibits metastatic progression. / Hurley, Paula; Hughes, Robert M.; Simons, Brian W.; Huang, Jessie; Miller, Rebecca M.; Shinder, Brian; Haffner, Michael C.; Esopi, David; Kimura, Yasunori; Jabbari, Javaneh; Ross, Ashley E.; Erho, Nicholas; Vergara, Ismael A.; Faraj, Sheila F.; Davicioni, Elai; Netto, George J.; Yegnasubramanian, S; An, Steven; Schaeffer, Edward M.

In: Cancer Research, Vol. 75, No. 20, 15.10.2015, p. 4322-4334.

Research output: Contribution to journalArticle

Hurley, P, Hughes, RM, Simons, BW, Huang, J, Miller, RM, Shinder, B, Haffner, MC, Esopi, D, Kimura, Y, Jabbari, J, Ross, AE, Erho, N, Vergara, IA, Faraj, SF, Davicioni, E, Netto, GJ, Yegnasubramanian, S, An, S & Schaeffer, EM 2015, 'Androgen-regulated SPARCL1 in the tumor microenvironment inhibits metastatic progression', Cancer Research, vol. 75, no. 20, pp. 4322-4334. https://doi.org/10.1158/0008-5472.CAN-15-0024
Hurley, Paula ; Hughes, Robert M. ; Simons, Brian W. ; Huang, Jessie ; Miller, Rebecca M. ; Shinder, Brian ; Haffner, Michael C. ; Esopi, David ; Kimura, Yasunori ; Jabbari, Javaneh ; Ross, Ashley E. ; Erho, Nicholas ; Vergara, Ismael A. ; Faraj, Sheila F. ; Davicioni, Elai ; Netto, George J. ; Yegnasubramanian, S ; An, Steven ; Schaeffer, Edward M. / Androgen-regulated SPARCL1 in the tumor microenvironment inhibits metastatic progression. In: Cancer Research. 2015 ; Vol. 75, No. 20. pp. 4322-4334.
@article{a40bf1b2ac164ce0930cf2819f302da3,
title = "Androgen-regulated SPARCL1 in the tumor microenvironment inhibits metastatic progression",
abstract = "Prostate cancer is a leading cause of cancer death in men due to the subset of cancers that progress to metastasis. Prostate cancers are thought to be hardwired to androgen receptor (AR) signaling, but AR-regulated changes in the prostate that facilitate metastasis remain poorly understood. We previously noted a marked reduction in secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) expression during invasive phases of androgen-induced prostate growth, suggesting that this may be a novel invasive program governed by AR. Herein, we show that SPARCL1 loss occurs concurrently with AR amplification or overexpression in patient-based data. Mechanistically we demonstrate that SPARCL1 expression is directly suppressed by androgen-induced AR activation and binding at the SPARCL1 locus via an epigenetic mechanism, and these events can be pharmacologically attenuated with either AR antagonists or HDAC inhibitors. We establish using the Hi-Myc model of prostate cancer that in Hi-Myc/Sparcl1-/-mice, SPARCL1 functions to suppress cancer formation. Moreover, metastatic progression of Myc-CaP orthotopic allografts is restricted by SPARCL1 in the tumor microenvironment. Specifically, we show that SPARCL1 both tethers to collagen in the extracellular matrix (ECM) and binds to the cell's cytoskeleton. SPARCL1 directly inhibits the assembly of focal adhesions, thereby constraining the transmission of cell traction forces. Our findings establish a new insight into AR-regulated prostate epithelial movement and provide a novel framework whereby SPARCL1 in the ECM microenvironment restricts tumor progression by regulating the initiation of the network of physical forces that may be required for metastatic invasion of prostate cancer.",
author = "Paula Hurley and Hughes, {Robert M.} and Simons, {Brian W.} and Jessie Huang and Miller, {Rebecca M.} and Brian Shinder and Haffner, {Michael C.} and David Esopi and Yasunori Kimura and Javaneh Jabbari and Ross, {Ashley E.} and Nicholas Erho and Vergara, {Ismael A.} and Faraj, {Sheila F.} and Elai Davicioni and Netto, {George J.} and S Yegnasubramanian and Steven An and Schaeffer, {Edward M.}",
year = "2015",
month = "10",
day = "15",
doi = "10.1158/0008-5472.CAN-15-0024",
language = "English (US)",
volume = "75",
pages = "4322--4334",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Androgen-regulated SPARCL1 in the tumor microenvironment inhibits metastatic progression

AU - Hurley, Paula

AU - Hughes, Robert M.

AU - Simons, Brian W.

AU - Huang, Jessie

AU - Miller, Rebecca M.

AU - Shinder, Brian

AU - Haffner, Michael C.

AU - Esopi, David

AU - Kimura, Yasunori

AU - Jabbari, Javaneh

AU - Ross, Ashley E.

AU - Erho, Nicholas

AU - Vergara, Ismael A.

AU - Faraj, Sheila F.

AU - Davicioni, Elai

AU - Netto, George J.

AU - Yegnasubramanian, S

AU - An, Steven

AU - Schaeffer, Edward M.

PY - 2015/10/15

Y1 - 2015/10/15

N2 - Prostate cancer is a leading cause of cancer death in men due to the subset of cancers that progress to metastasis. Prostate cancers are thought to be hardwired to androgen receptor (AR) signaling, but AR-regulated changes in the prostate that facilitate metastasis remain poorly understood. We previously noted a marked reduction in secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) expression during invasive phases of androgen-induced prostate growth, suggesting that this may be a novel invasive program governed by AR. Herein, we show that SPARCL1 loss occurs concurrently with AR amplification or overexpression in patient-based data. Mechanistically we demonstrate that SPARCL1 expression is directly suppressed by androgen-induced AR activation and binding at the SPARCL1 locus via an epigenetic mechanism, and these events can be pharmacologically attenuated with either AR antagonists or HDAC inhibitors. We establish using the Hi-Myc model of prostate cancer that in Hi-Myc/Sparcl1-/-mice, SPARCL1 functions to suppress cancer formation. Moreover, metastatic progression of Myc-CaP orthotopic allografts is restricted by SPARCL1 in the tumor microenvironment. Specifically, we show that SPARCL1 both tethers to collagen in the extracellular matrix (ECM) and binds to the cell's cytoskeleton. SPARCL1 directly inhibits the assembly of focal adhesions, thereby constraining the transmission of cell traction forces. Our findings establish a new insight into AR-regulated prostate epithelial movement and provide a novel framework whereby SPARCL1 in the ECM microenvironment restricts tumor progression by regulating the initiation of the network of physical forces that may be required for metastatic invasion of prostate cancer.

AB - Prostate cancer is a leading cause of cancer death in men due to the subset of cancers that progress to metastasis. Prostate cancers are thought to be hardwired to androgen receptor (AR) signaling, but AR-regulated changes in the prostate that facilitate metastasis remain poorly understood. We previously noted a marked reduction in secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) expression during invasive phases of androgen-induced prostate growth, suggesting that this may be a novel invasive program governed by AR. Herein, we show that SPARCL1 loss occurs concurrently with AR amplification or overexpression in patient-based data. Mechanistically we demonstrate that SPARCL1 expression is directly suppressed by androgen-induced AR activation and binding at the SPARCL1 locus via an epigenetic mechanism, and these events can be pharmacologically attenuated with either AR antagonists or HDAC inhibitors. We establish using the Hi-Myc model of prostate cancer that in Hi-Myc/Sparcl1-/-mice, SPARCL1 functions to suppress cancer formation. Moreover, metastatic progression of Myc-CaP orthotopic allografts is restricted by SPARCL1 in the tumor microenvironment. Specifically, we show that SPARCL1 both tethers to collagen in the extracellular matrix (ECM) and binds to the cell's cytoskeleton. SPARCL1 directly inhibits the assembly of focal adhesions, thereby constraining the transmission of cell traction forces. Our findings establish a new insight into AR-regulated prostate epithelial movement and provide a novel framework whereby SPARCL1 in the ECM microenvironment restricts tumor progression by regulating the initiation of the network of physical forces that may be required for metastatic invasion of prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84945910175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945910175&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-0024

DO - 10.1158/0008-5472.CAN-15-0024

M3 - Article

VL - 75

SP - 4322

EP - 4334

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 20

ER -